Literature DB >> 21989989

Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia.

Pekka Jaako1, Johan Flygare, Karin Olsson, Ronan Quere, Mats Ehinger, Adrianna Henson, Steven Ellis, Axel Schambach, Christopher Baum, Johan Richter, Jonas Larsson, David Bryder, Stefan Karlsson.   

Abstract

Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia caused by a functional haploinsufficiency of genes encoding for ribosomal proteins. Among these genes, ribosomal protein S19 (RPS19) is mutated most frequently. Generation of animal models for diseases like DBA is challenging because the phenotype is highly dependent on the level of RPS19 down-regulation. We report the generation of mouse models for RPS19-deficient DBA using transgenic RNA interference that allows an inducible and graded down-regulation of Rps19. Rps19-deficient mice develop a macrocytic anemia together with leukocytopenia and variable platelet count that with time leads to the exhaustion of hematopoietic stem cells and bone marrow failure. Both RPS19 gene transfer and the loss of p53 rescue the DBA phenotype implying the potential of the models for testing novel therapies. This study demonstrates the feasibility of transgenic RNA interference to generate mouse models for human diseases caused by haploinsufficient expression of a gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989989     DOI: 10.1182/blood-2011-08-371963

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  Delayed globin synthesis leads to excess heme and the macrocytic anemia of Diamond Blackfan anemia and del(5q) myelodysplastic syndrome.

Authors:  Zhantao Yang; Siobán B Keel; Akiko Shimamura; Li Liu; Aaron T Gerds; Henry Y Li; Brent L Wood; Bart L Scott; Janis L Abkowitz
Journal:  Sci Transl Med       Date:  2016-05-11       Impact factor: 17.956

2.  Ribosome biogenesis dysfunction leads to p53-mediated apoptosis and goblet cell differentiation of mouse intestinal stem/progenitor cells.

Authors:  A Stedman; S Beck-Cormier; M Le Bouteiller; A Raveux; S Vandormael-Pournin; S Coqueran; V Lejour; L Jarzebowski; F Toledo; S Robine; M Cohen-Tannoudji
Journal:  Cell Death Differ       Date:  2015-06-12       Impact factor: 15.828

3.  Scission of the p53-MDM2 Loop by Ribosomal Proteins.

Authors:  Xiang Zhou; Jun-Ming Liao; Wen-Juan Liao; Hua Lu
Journal:  Genes Cancer       Date:  2012-03

Review 4.  Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications.

Authors:  Wei Wang; Subhasree Nag; Xu Zhang; Ming-Hai Wang; Hui Wang; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2014-08-28       Impact factor: 12.944

5.  MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction.

Authors:  Jad I Belle; HanChen Wang; Amanda Fiore; Jessica C Petrov; Yun Hsiao Lin; Chu-Han Feng; Thi Tuyet Mai Nguyen; Jacky Tung; Philippe M Campeau; Uta Behrends; Theresa Brunet; Gloria Sarah Leszinski; Philippe Gros; David Langlais; Anastasia Nijnik
Journal:  JCI Insight       Date:  2020-07-09

Review 6.  GRWD1, a new player among oncogenesis-related ribosomal/nucleolar proteins.

Authors:  Takuya Takafuji; Kota Kayama; Nozomi Sugimoto; Masatoshi Fujita
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

7.  Lentiviral Vectors with Cellular Promoters Correct Anemia and Lethal Bone Marrow Failure in a Mouse Model for Diamond-Blackfan Anemia.

Authors:  Shubhranshu Debnath; Pekka Jaako; Kavitha Siva; Michael Rothe; Jun Chen; Maria Dahl; H Bobby Gaspar; Johan Flygare; Axel Schambach; Stefan Karlsson
Journal:  Mol Ther       Date:  2017-04-20       Impact factor: 11.454

Review 8.  Ribosomal biogenesis as an emerging target of neurodevelopmental pathologies.

Authors:  Michal Hetman; Lukasz P Slomnicki
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

9.  Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes.

Authors:  Aparna Raval; Kunju J Sridhar; Shripa Patel; Brit B Turnbull; Peter L Greenberg; Beverly S Mitchell
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

Review 10.  CRISPR-Cas9 technology and its application in haematological disorders.

Authors:  Han Zhang; Nami McCarty
Journal:  Br J Haematol       Date:  2016-09-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.